Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL394481 | 1.00 | PIK3CA (0.72) | PIK3CAMTOR | |
| SCHEMBL7914957 | 0.94 | PIK3CA (0.80) | PIK3CAMTOR | |
| SCHEMBL396272 | 0.94 | PIK3CA (0.80) | PIK3CAMTOR | |
| SCHEMBL391472 | 0.94 | PIK3CA (0.80) | PIK3CAMTOR | |
| SCHEMBL396260 | 0.90 | PIK3CA (0.90) | PIK3CAMTOR | |
| SCHEMBL395854 | 0.90 | PIK3CA (0.74) | PIK3CAMTOR | |
| SCHEMBL395045 | 0.90 | PIK3CA (0.74) | PIK3CAMTOR | |
| SCHEMBL394343 | 0.89 | PIK3CA (0.80) | PIK3CAMTOR | |
| SCHEMBL8210463 | 0.84 | PIK3CA (1.00) | PIK3CAMTOR | |
| SCHEMBL3725543 | 0.84 | PIK3CA (0.59) | PIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101622-B2 | Pyridopyrimidinone inhibitors of PI3Kα and mTOR | EXELIXIS, INC. (US) | 2012-01-24 | — | — | US | claimed |
| EP-2350070-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3K AND MTOR | Exelixis, Inc. (US) | 2011-08-03 | — | — | EP | claimed |
| US-20100087456-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3K-ALPHA and mTOR | EXELIXIS, INC. (US) | 2010-04-08 | — | — | US | claimed |
| WO-2010039740-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα AND MTOR | EXELIXIS, INC. (US) | 2010-04-08 | — | — | WO | claimed |
| US-8101622-B2 | Pyridopyrimidinone inhibitors of PI3Kα and mTOR | EXELIXIS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101622-B2 | Pyridopyrimidinone inhibitors of PI3Kα and mTOR | EXELIXIS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8101622-B2 | Pyridopyrimidinone inhibitors of PI3Kα and mTOR | EXELIXIS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20100087456-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3K-ALPHA and mTOR | EXELIXIS, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087456-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3K-ALPHA and mTOR | EXELIXIS, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| US-20100087456-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3K-ALPHA and mTOR | EXELIXIS, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| WO-2010039740-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα AND MTOR | EXELIXIS, INC. (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087456-A1 | PYRIDOPYRIMIDINONE INHIBITORS OF PI3K-ALPHA and mTOR | PIK3CD, PIK3CA, MTOR | PIK3CA 2/4885MTOR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.